USA - NYSEARCA:KNW - US4992382022 - Common Stock
The current stock price of KNW is 2.14 USD. In the past month the price decreased by -19.25%. In the past year, price increased by 397.67%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25 | 217.12B | ||
| ISRG | INTUITIVE SURGICAL INC | 62.8 | 193.84B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.95 | 148.41B | ||
| SYK | STRYKER CORP | 28.96 | 142.26B | ||
| MDT | MEDTRONIC PLC | 16.63 | 117.99B | ||
| BDX | BECTON DICKINSON AND CO | 12.79 | 52.33B | ||
| IDXX | IDEXX LABORATORIES INC | 52.5 | 50.44B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.09 | 48.42B | ||
| RMD | RESMED INC | 26.84 | 37.40B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.73 | 35.59B | ||
| DXCM | DEXCOM INC | 40.46 | 26.98B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.6 | 26.70B |
Know Labs, Inc. engages in the development, marketing, and sale of a photonics technology. The company is headquartered in Seattle, Washington and currently employs 7 full-time employees. The company went IPO on 2006-04-12. The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology is designed to be able to integrate into a variety of wearable, mobile or bench-top form factors. Its patent-pending technology makes it possible to identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The Company’s expected application of the technology is focused on a product marketed as a non-invasive glucose monitor. The device is designed to provide the user with accessible and affordable real-time information on blood glucose levels. Its sensor technology embodies two key components: hardware and software. The hardware component includes a sensor which both sends and receives a radio frequency signal. The Company’s wholly owned subsidiary is Particle, Inc.
KNOW LABS INC
619 Western Avenue, Suite 610
Seattle WASHINGTON US
Employees: 6
Phone: 12069031351
Know Labs, Inc. engages in the development, marketing, and sale of a photonics technology. The company is headquartered in Seattle, Washington and currently employs 7 full-time employees. The company went IPO on 2006-04-12. The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology is designed to be able to integrate into a variety of wearable, mobile or bench-top form factors. Its patent-pending technology makes it possible to identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The Company’s expected application of the technology is focused on a product marketed as a non-invasive glucose monitor. The device is designed to provide the user with accessible and affordable real-time information on blood glucose levels. Its sensor technology embodies two key components: hardware and software. The hardware component includes a sensor which both sends and receives a radio frequency signal. The Company’s wholly owned subsidiary is Particle, Inc.
The current stock price of KNW is 2.14 USD. The price increased by 3.88% in the last trading session.
KNW does not pay a dividend.
KNW has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
KNW stock is listed on the NYSE Arca exchange.
KNOW LABS INC (KNW) currently has 6 employees.
KNOW LABS INC (KNW) will report earnings on 2025-11-12, after the market close.
ChartMill assigns a technical rating of 7 / 10 to KNW. When comparing the yearly performance of all stocks, KNW is one of the better performing stocks in the market, outperforming 99.51% of all stocks.
Over the last trailing twelve months KNW reported a non-GAAP Earnings per Share(EPS) of -5.03. The EPS increased by 42.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3181.63% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
5 analysts have analysed KNW and the average price target is 40.8 USD. This implies a price increase of 1806.54% is expected in the next year compared to the current price of 2.14.